Biopharmx (NYSEAMERICAN:BPMX) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Biopharmx (NYSEAMERICAN:BPMX) released its quarterly earnings data on Monday. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.12, Fidelity Earnings reports.

Shares of NYSEAMERICAN BPMX traded down $0.01 on Tuesday, hitting $0.39. The company’s stock had a trading volume of 12,946 shares, compared to its average volume of 610,260. Biopharmx has a 12-month low of $0.30 and a 12-month high of $6.75.

Separately, Maxim Group set a $3.00 price objective on shares of Biopharmx and gave the company a “buy” rating in a research note on Tuesday, June 25th.

In other news, major shareholder Vivo Capital Viii, Llc sold 327,870 shares of the stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $1.02, for a total value of $334,427.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

About Biopharmx

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Featured Article: If I purchase shares through a brokerage account, am I the holder of record?

Earnings History for Biopharmx (NYSEAMERICAN:BPMX)

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.